reports
- Dave Nicoski
- Ross LaDuke
Vermilion Compass: Weekly Equity Strategy
U.S. Dollar (DXY) Rolling Over Large-cap indexes (S&P 500, Nasdaq 100, and DJI) remain bullish, all hitting new all-time highs last week while continuing to find short-term support at their respective 20-day MAs. Mid-caps (S&P 400, Russell Mid-Cap) are starting another leg higher following breakouts from 2-month consolidations. Small-caps (S&P 600, Russell 2000) are likely to follow in the footsteps of large- and mid-caps, and are likely to break out from their 2.5-month consolidations/high bas...
WWW WOLVERINE WORLD WIDE INC.
TEVA.N TEVA PHARMACEUTICAL INDUSTRIES LIMITED SPONSORED ADR
SHOO STEVEN MADDEN LTD.
RCKY ROCKY BRANDS
MAR MARRIOTT INTERNATIONAL INC. CLASS A
H HYATT HOTELS CORPORATION CLASS A
GPS GAP INC.
ANF ABERCROMBIE & FITCH CO. CLASS A
AEO AMERICAN EAGLE OUTFITTERS INC.
TARO TARO PHARMACEUTICAL INDUSTRIES LTD.
WEYS WEYCO GROUP INC.
HGV HILTON GRAND VACATIONS INC.
HLT HILTON WORLDWIDE HOLDINGS INC
AMRX AMNEAL PHARMACEUTICALS INC. CLASS A
HTHT HUAZHU GROUP LTD. SPONSORED ADR
VTRS VIATRIS INC.
IHG INTERCONTINENTAL HOTELS GROUP
- Dave Nicoski
- Ross LaDuke
Vermilion Compass: Weekly Equity Strategy
Upgrading Staples and Health Care to Market Weight As the saying goes, "sector rotation is the lifeblood of a bull market." That appears to be exactly what is going on as we kick off 2024. Leadership areas that have significantly outperformed since the October 2023 lows are starting to pull back rather hard -- and on above average volume. This includes areas such as Technology (XLK), semiconductors (SMH), software (IGV), and the ARKK, IPO, and BITQ ETFs. This tells us a pause/pullback is likely...
RGEN REPLIGEN CORPORATION
POST POST HOLDINGS INC.
NBIX NEUROCRINE BIOSCIENCES INC.
MDLZ MONDELEZ INTERNATIONAL INC. CLASS A
KHC KRAFT HEINZ COMPANY
K KELLOGG COMPANY
ITCI INTRA-CELLULAR THERAPIES INC.
EXEL EXELIXIS INC.
CPB CAMPBELL SOUP COMPANY
CAG CONAGRA BRANDS INC.
TARO TARO PHARMACEUTICAL INDUSTRIES LTD.
IONS IONIS PHARMACEUTICALS INC.
THS TREEHOUSE FOODS INC.
SJM J.M. SMUCKER COMPANY
CRSP CRISPR THERAPEUTICS AG
NOMDN NOMAD FOODS LTD.
ASND ASCENDANT RESOURCES INC
AMRX AMNEAL PHARMACEUTICALS INC. CLASS A
PCVX VAXCYTE
VTRS VIATRIS INC.
Taro to Announce Full Year Results on May 17, 2018
HAWTHORNE, N.Y.--(BUSINESS WIRE)-- Taro Pharmaceutical Industries Ltd. (NYSE:TARO) announced today that it plans to release its financial results for year ended March 31, 2018, on Thursday, May 17, 2018. The Company will conduct an earnings call at 8:00 am EDT on Friday, May 18, 2018, where senior management will discuss the Company’s performance and answer questions from participants. The release will be accessible on Taro’s website at www.taro.com. Earnings Call (8:00 am EDT on Friday, May 18, 2018)...
Taro Provides Results for December 31, 2017
HAWTHORNE, N.Y.--(BUSINESS WIRE)-- Taro Pharmaceutical Industries Ltd. (NYSE:TARO) (“Taro” or the “Company”) today provided unaudited financial results for the three and nine months ended December 31, 2017. Quarter ended December 31, 2017 Highlights ─ compared to December 31, 2016 Net sales of $155.5 million decreased $64.9 million, the result of continuing increased competition and the challenging pricing environment, particularly in the U.S.; despite an increase in overall volumes. ...
Taro to Announce Third Quarter Results on February 7, 2018
HAWTHORNE, N.Y.--(BUSINESS WIRE)-- Taro Pharmaceutical Industries Ltd. (NYSE: TARO) announced today that it plans to release its financial results for the quarter and nine months ended December 31, 2017, after the close of market on Wednesday, February 7, 2018. The release will be accessible on Taro’s website at www.taro.com. About Taro Taro Pharmaceutical Industries Ltd. is a multinational, science-based pharmaceutical company, dedicated to meeting the needs of its customers through the discovery, de...
Taro Provides Results for September 30, 2017
HAWTHORNE, N.Y.--(BUSINESS WIRE)-- November 7, 2017-- Taro Pharmaceutical Industries Ltd. (NYSE:TARO) (“Taro” or the “Company”) today provided unaudited financial results for the three and six months ended September 30, 2017. Quarter ended September 30, 2017 Highlights - compared to September 30, 2016 Net sales of $169.9 million decreased $58.9 million, the result of continuing increased competition and the challenging pricing environment; despite a slight increase in volumes. Gross...
Taro to Announce Second Quarter Results on November 7, 2017
HAWTHORNE, N.Y.--(BUSINESS WIRE)-- Taro Pharmaceutical Industries Ltd. (NYSE:TARO) ("TARO" or the "Company") announced today that it plans to release its financial results for the quarter and six months ended September 30, 2017, on Tuesday, November 7, 2017. The Company will conduct an earnings call at 8:00 am EST on Wednesday, November 8, 2017, where senior management will discuss the Company’s performance and answer questions from participants. The release will be accessible on Taro’s website at www.taro.com. ...
Taro Announces Joining of CEO
HAWTHORNE, N.Y.--(BUSINESS WIRE)-- Taro Pharmaceutical Industries Ltd. (NYSE:TARO) (“Taro” or the “Company”) announced today that Mr. Uday Baldota has joined the Company as its Chief Executive Officer (“CEO”) effective August 28, 2017. Since December 2016, Mr. Baldota has served as a member of Taro’s Board of Directors (“Taro Board”). Mr. Baldota replaces Mr. Abhay Gandhi, who served in the role of Interim Chief Executive Officer since January 1, 2017. Mr. Gandhi will continue in his role as Vice Chairman of the Taro Board an...
Taro Provides Results for Quarter Ended June 2017
HAWTHORNE, N.Y.--(BUSINESS WIRE)-- Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro” or the “Company”) today provided unaudited financial results for the quarter ended June 30, 2017. Quarter ended June 30, 2017 Highlights - compared to June 30, 2016 Net sales of $161.3 million, decreased $72.5 million, or 31.0%, the result of continuing increased competition and the challenging pricing environment; despite an overall increase in volumes. Gross profit of $116.5 million, decreased $66...
Taro to Announce First Quarter Results on August 8, 2017
HAWTHORNE, N.Y.--(BUSINESS WIRE)-- Taro Pharmaceutical Industries Ltd. (NYSE:TARO) announced today that it plans to release its financial results for the quarter ended June 30, 2017, after the close of market on Tuesday, August 8, 2017. Consistent with the Company’s policy, Taro will conduct its next earnings call when it announces its financial results for the six months ending September 30, 2017. The release will be accessible on Taro’s website at www.taro.com. About Taro Taro Pharmaceutical Industr...
Taro Annual Report on Form 20-F Available for Fiscal Year Ended March ...
HAWTHORNE, N.Y.--(BUSINESS WIRE)-- Taro Pharmaceutical Industries Ltd. (NYSE:TARO, “Taro”) announced that its Annual Report on Form 20-F for the fiscal year ended March 31, 2017, filed with the Securities and Exchange Commission (the “SEC”), is available within the Investor Relations section of Taro’s website at www.taro.com. Hard copies of the report may be ordered free of charge by sending requests to: Taro Pharmaceuticals U.S.A., Inc.Three Skyline DriveHawthorne, NY 10532attention: William J. Coote orvia email to ...
Taro Provides Results for Year Ended March 31, 2017
HAWTHORNE, N.Y.--(BUSINESS WIRE)-- Taro Pharmaceutical Industries Ltd. (NYSE:TARO) (“Taro” or the “Company”) today provided unaudited financial results for the quarter and fiscal year ended March 31, 2017. Quarter ended March 31, 2017 Highlights - compared to March 31, 2016 Net sales of $196.4 million, decreased $68.7 million, or 25.9%, the result of continuing increased competition and the challenging pricing environment. Overall volumes increased 3%. Gross profit of $143.8 million decrea...
Taro to Announce Results for Year Ended March 31, 2017 on May 22, 2017
HAWTHORNE, N.Y.--(BUSINESS WIRE)-- Taro Pharmaceutical Industries Ltd. (NYSE:TARO) announced today that it plans to release its financial results for the fiscal year ended March 31, 2017, on Monday, May 22, 2017. The Company will conduct an earnings call at 8:00 am EDT on Tuesday, May 23, 2017, where senior management will discuss the Company’s performance and answer questions from participants. The release will be accessible on Taro’s website at www.taro.com. Earnings Call (8:00 am EDT on Tuesday, Ma...
Taro Provides Results for December 31, 2016
HAWTHORNE, N.Y.--(BUSINESS WIRE)-- Taro Pharmaceutical Industries Ltd. (NYSE:TARO) (“Taro” or the “Company”) today provided unaudited financial results for the three and nine months ended December 31, 2016. Quarter ended December 31, 2016 Highlights - compared to December 31, 2015 Net sales of $220.4 million, decreased $37.9 million, or 14.7%, the result of continuing increased competition and the challenging pricing environment. Overall volumes increased 1%. Gross profit of $167.3 ...
Taro to Announce Third Quarter Results on February 9, 2017
HAWTHORNE, N.Y.--(BUSINESS WIRE)-- Taro Pharmaceutical Industries Ltd. (NYSE:TARO) announced today that it plans to release its financial results for the quarter and nine months ended December 31, 2016, after the close of market on Thursday, February 9, 2017. Consistent with the Company’s policy, Taro will conduct its next earnings call when it announces its financial results for the year-ending March 31, 2017. The release will be accessible on Taro’s website at www.taro.com. About Taro ...
TARO 72 HOUR DEADLINE ALERT: Approximately 72 Hours Remain; Former Lou...
NEW ORLEANS--(BUSINESS WIRE)-- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with large financial interests that they have only until December 26, 2016 to file lead plaintiff applications in a securities class action lawsuit against Taro Pharmaceutical Industries Ltd. (NYSE: TARO). Investor losses must relate to purchases of the Company’s securities between July 3, 2014 and September 9, 2016. This action is pending in the United States District Court fo...
Taro Announces Sale of U.S. Rights to Keveyis® to Strongbridge Biopha...
HAWTHORNE, N.Y.--(BUSINESS WIRE)-- Taro Pharmaceutical Industries Ltd. (NYSE:TARO) (“Taro” or the “Company”) today announced the sale of U.S. rights to Keveyis® (dichlorphenamide) to Strongbridge Biopharma plc (Strongbridge), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet need. Keveyis was approved by the U.S. Food and Drug Administration (the “FDA”) in August 2015 to treat primary hyperkalemic and hypokalemic periodic paralysis...
Ford Equity US Rating and Forecast Report
Ford Equity Research covers more than 4,000 stocks using a proprietary quantitative model that evaluates a company’s earnings strength, its relative valuation and recent price movement. Ford’s five recommendation ratings include strong buy, buy, hold, sell, strong sell. For all stocks in our coverage universe, ratings are generated each week and reflect the fundamental and price data as of the last trading day of the week.
Ford Equity International Rating and Forecast Report
Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind...
SHAREHOLDER REMINDER: Kessler Topaz Meltzer & Check, LLP Announces Dea...
RADNOR, Pa.--(BUSINESS WIRE)-- The law firm of Kessler Topaz Meltzer & Check, LLP reminds Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro” or the “Company”) shareholders that a class action lawsuit has been filed on behalf of purchasers of the Company’s securities between July 3, 2014 and September 9, 2016, inclusive (the “Class Period”). REMINDER: Taro shareholders who purchased securities during the Class Period may, no later than December 26, 2016, petition the Court to be appointed as a lead plaintiff representati...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.